COVID-19 Severity Test
Predicting Disease Severity in Hospitalized COVID-19 Patients
DevelopmentLDT; Limited commercial use
Key Facts
Indication
Predicting Disease Severity in Hospitalized COVID-19 Patients
Phase
Development
Status
LDT; Limited commercial use
Company
About Biodesix
Biodesix is a data-driven diagnostic company that integrates proteomics, genomics, and artificial intelligence to deliver real-world diagnostic solutions for lung disease. The company has a commercial portfolio of blood-based tests, including the Nodify XL2® and Nodify CDT® tests for lung nodule management, and the GeneStrat® and VeriStrat® tests for therapy selection in NSCLC. Its strategy centers on expanding the clinical utility of its tests, driving adoption, and leveraging its proprietary Biodesix Lung Database® to develop new diagnostic products.
View full company profile